Research ArticleClinical Investigation
Detection of Bone Metastases in Patients with Endocrine Gastroenteropancreatic Tumors: Bone Scintigraphy Compared with Somatostatin Receptor Scintigraphy
Rachida Lebtahi, Guillaume Cadiot, Nicolas Delahaye, Remy Genin, Doumit Daou, Muammer C. Peker, Denis Chosidow, Marc Faraggi, Michel Mignon and Dominique Le Guludec
Journal of Nuclear Medicine October 1999, 40 (10) 1602-1608;
Rachida Lebtahi
Guillaume Cadiot
Nicolas Delahaye
Remy Genin
Doumit Daou
Muammer C. Peker
Denis Chosidow
Marc Faraggi
Michel Mignon
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Detection of Bone Metastases in Patients with Endocrine Gastroenteropancreatic Tumors: Bone Scintigraphy Compared with Somatostatin Receptor Scintigraphy
Rachida Lebtahi, Guillaume Cadiot, Nicolas Delahaye, Remy Genin, Doumit Daou, Muammer C. Peker, Denis Chosidow, Marc Faraggi, Michel Mignon, Dominique Le Guludec
Journal of Nuclear Medicine Oct 1999, 40 (10) 1602-1608;
Detection of Bone Metastases in Patients with Endocrine Gastroenteropancreatic Tumors: Bone Scintigraphy Compared with Somatostatin Receptor Scintigraphy
Rachida Lebtahi, Guillaume Cadiot, Nicolas Delahaye, Remy Genin, Doumit Daou, Muammer C. Peker, Denis Chosidow, Marc Faraggi, Michel Mignon, Dominique Le Guludec
Journal of Nuclear Medicine Oct 1999, 40 (10) 1602-1608;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Bone metastases and skeletal-related events from neuroendocrine tumors
- Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions
- Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
- Bone Metastases in Carcinoid Tumors: Clinical Features, Imaging Characteristics, and Markers of Bone Metabolism
- Detection of Neuroendocrine Tumors: 99mTc-P829 Scintigraphy Compared with 111In-Pentetreotide Scintigraphy
- The New Technology of Combined Transmission and Emission Tomography in Evaluation of Endocrine Neoplasms